199 related articles for article (PubMed ID: 26661196)
1. A novel quantitative high-throughput screen identifies drugs that both activate SUMO conjugation via the inhibition of microRNAs 182 and 183 and facilitate neuroprotection in a model of oxygen and glucose deprivation.
Bernstock JD; Lee YJ; Peruzzotti-Jametti L; Southall N; Johnson KR; Maric D; Volpe G; Kouznetsova J; Zheng W; Pluchino S; Hallenbeck JM
J Cereb Blood Flow Metab; 2016 Feb; 36(2):426-41. PubMed ID: 26661196
[TBL] [Abstract][Full Text] [Related]
2. Global SUMOylation facilitates the multimodal neuroprotection afforded by quercetin against the deleterious effects of oxygen/glucose deprivation and the restoration of oxygen/glucose.
Lee YJ; Bernstock JD; Nagaraja N; Ko B; Hallenbeck JM
J Neurochem; 2016 Jul; 138(1):101-16. PubMed ID: 27087120
[TBL] [Abstract][Full Text] [Related]
3. Global protein conjugation by ubiquitin-like-modifiers during ischemic stress is regulated by microRNAs and confers robust tolerance to ischemia.
Lee YJ; Johnson KR; Hallenbeck JM
PLoS One; 2012; 7(10):e47787. PubMed ID: 23094087
[TBL] [Abstract][Full Text] [Related]
4. Quantitative high-throughput screening identifies cytoprotective molecules that enhance SUMO conjugation via the inhibition of SUMO-specific protease (SENP)2.
Bernstock JD; Ye D; Smith JA; Lee YJ; Gessler FA; Yasgar A; Kouznetsova J; Jadhav A; Wang Z; Pluchino S; Zheng W; Simeonov A; Hallenbeck JM; Yang W
FASEB J; 2018 Mar; 32(3):1677-1691. PubMed ID: 29146736
[TBL] [Abstract][Full Text] [Related]
5. Development of a high-throughput screening assay for inhibitors of small ubiquitin-like modifier proteases.
Yang W; Wang L; Paschen W
J Biomol Screen; 2013 Jun; 18(5):621-8. PubMed ID: 23470489
[TBL] [Abstract][Full Text] [Related]
6. SUMO and ischemic tolerance.
Lee YJ; Hallenbeck JM
Neuromolecular Med; 2013 Dec; 15(4):771-81. PubMed ID: 23775726
[TBL] [Abstract][Full Text] [Related]
7. Small molecule SUMOylation activators are novel neuroprotective agents.
Krajnak K; Dahl R
Bioorg Med Chem Lett; 2018 Feb; 28(3):405-409. PubMed ID: 29269215
[TBL] [Abstract][Full Text] [Related]
8. SUMO2/3 conjugation is an endogenous neuroprotective mechanism.
Datwyler AL; Lättig-Tünnemann G; Yang W; Paschen W; Lee SL; Dirnagl U; Endres M; Harms C
J Cereb Blood Flow Metab; 2011 Nov; 31(11):2152-9. PubMed ID: 21863037
[TBL] [Abstract][Full Text] [Related]
9. Morphine Preconditioning Downregulates MicroRNA-134 Expression Against Oxygen-Glucose Deprivation Injuries in Cultured Neurons of Mice.
Meng F; Li Y; Chi W; Li J
J Neurosurg Anesthesiol; 2016 Jul; 28(3):195-202. PubMed ID: 26372418
[TBL] [Abstract][Full Text] [Related]
10. Protein SUMOylation is massively increased in hibernation torpor and is critical for the cytoprotection provided by ischemic preconditioning and hypothermia in SHSY5Y cells.
Lee YJ; Miyake S; Wakita H; McMullen DC; Azuma Y; Auh S; Hallenbeck JM
J Cereb Blood Flow Metab; 2007 May; 27(5):950-62. PubMed ID: 16955077
[TBL] [Abstract][Full Text] [Related]
11. Global SUMOylation is a molecular mechanism underlying hypothermia-induced ischemic tolerance.
Lee YJ; Mou Y; Klimanis D; Bernstock JD; Hallenbeck JM
Front Cell Neurosci; 2014; 8():416. PubMed ID: 25538566
[TBL] [Abstract][Full Text] [Related]
12. Guanosine modulates SUMO2/3-ylation in neurons and astrocytes via adenosine receptors.
Zanella CA; Tasca CI; Henley JM; Wilkinson KA; Cimarosti HI
Purinergic Signal; 2020 Sep; 16(3):439-450. PubMed ID: 32892251
[TBL] [Abstract][Full Text] [Related]
13. Analysis of oxygen/glucose-deprivation-induced changes in SUMO3 conjugation using SILAC-based quantitative proteomics.
Yang W; Thompson JW; Wang Z; Wang L; Sheng H; Foster MW; Moseley MA; Paschen W
J Proteome Res; 2012 Feb; 11(2):1108-17. PubMed ID: 22082260
[TBL] [Abstract][Full Text] [Related]
14. SUMOylation participates in induction of ischemic tolerance.
Lee YJ; Castri P; Bembry J; Maric D; Auh S; Hallenbeck JM
J Neurochem; 2009 Apr; 109(1):257-67. PubMed ID: 19200349
[TBL] [Abstract][Full Text] [Related]
15. Targeting the SUMO pathway for neuroprotection in brain ischaemia.
Yang W; Sheng H; Wang H
Stroke Vasc Neurol; 2016 Sep; 1(3):101-107. PubMed ID: 28959470
[TBL] [Abstract][Full Text] [Related]
16. Sumo-2/3-ylation following in vitro modeled ischemia is reduced in delayed ischemic tolerance.
Loftus LT; Gala R; Yang T; Jessick VJ; Ashley MD; Ordonez AN; Thompson SJ; Simon RP; Meller R
Brain Res; 2009 May; 1272():71-80. PubMed ID: 19332039
[TBL] [Abstract][Full Text] [Related]
17. Small ubiquitin-like modifier 3-modified proteome regulated by brain ischemia in novel small ubiquitin-like modifier transgenic mice: putative protective proteins/pathways.
Yang W; Sheng H; Thompson JW; Zhao S; Wang L; Miao P; Liu X; Moseley MA; Paschen W
Stroke; 2014 Apr; 45(4):1115-22. PubMed ID: 24569813
[TBL] [Abstract][Full Text] [Related]
18. The role of SUMOylation in cerebral hypoxia and ischemia.
Peters M; Wielsch B; Boltze J
Neurochem Int; 2017 Jul; 107():66-77. PubMed ID: 28323006
[TBL] [Abstract][Full Text] [Related]
19. Identification of sumoylation activating enzyme 1 inhibitors by structure-based virtual screening.
Kumar A; Ito A; Hirohama M; Yoshida M; Zhang KY
J Chem Inf Model; 2013 Apr; 53(4):809-20. PubMed ID: 23544417
[TBL] [Abstract][Full Text] [Related]
20. An in vitro Förster resonance energy transfer-based high-throughput screening assay identifies inhibitors of SUMOylation E2 Ubc9.
Wang YZ; Liu X; Way G; Madarha V; Zhou QT; Yang DH; Liao JY; Wang MW
Acta Pharmacol Sin; 2020 Nov; 41(11):1497-1506. PubMed ID: 32341466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
